Literature DB >> 20723990

Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases.

Carol L Shields1, Jeremy S Markowitz, Irina Belinsky, Hal Schwartzstein, Nina S George, Sara E Lally, Arman Mashayekhi, Jerry A Shields.   

Abstract

PURPOSE: To evaluate prognostic factors based on origin of conjunctival melanoma.
DESIGN: Interventional case series. PARTICIPANTS: Three hundred eighty-two consecutive patients.
METHODS: Retrospective chart review. MAIN OUTCOME MEASURES: Melanoma-related metastasis and death.
RESULTS: The melanoma arose from primary acquired melanosis (PAM; n = 284; 74%), from pre-existing nevus (n = 26; 7%), and de novo (n = 72; 19%). The mean tumor base was 11 mm for melanoma arising from PAM, 6 mm for melanoma arising from nevus, and 10 mm for those arising de novo. At 5 years (10 years), melanoma metastasis occurred in 19% (25%) in melanoma arising from PAM (P = 0.003), 10% (26%) in melanoma from nevus (P = 0.193), and 35% (49%) in those de novo. Factors predictive of metastasis by multivariable analysis included tumor origin de novo (P = 0.001), palpebral location (P<0.001), nodular tumor (P = 0.005), and orbital invasion (P = 0.022). At 5 years (10 years), melanoma-related death occurred in 5% (9%) in melanoma arising from PAM (P<0.001), 0% (9%) in melanoma arising from nevus (P<0.057), and 17% (35%) in those arising de novo. Factors predictive of death by multivariable analysis included tumor origin de novo (P<0.001), fornix location (P = 0.04), and nodular tumor (P = 0.001).
CONCLUSIONS: Melanoma arising de novo carries a higher risk of melanoma-related metastasis and death compared with those cases arising from PAM or nevus.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20723990     DOI: 10.1016/j.ophtha.2010.06.021

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  47 in total

1.  Sinonasal melanoma arising from conjunctival primary acquired melanosis.

Authors:  Mark Shehata; Dan Gombos; John Bishop; Mark Edwin Zafereo
Journal:  BMJ Case Rep       Date:  2015-02-18

Review 2.  Updates in Ocular Surface Tumor Diagnostics.

Authors:  Afshan A Nanji; Carolina Mercado; Anat Galor; Sander Dubovy; Carol L Karp
Journal:  Int Ophthalmol Clin       Date:  2017

3.  Management of conjunctival malignant melanoma: a review and update.

Authors:  James R Wong; Afshan A Nanji; Anat Galor; Carol L Karp
Journal:  Expert Rev Ophthalmol       Date:  2014-06

Review 4.  Advances in the management of conjunctival melanoma.

Authors:  Gargi K Vora; Hakan Demirci; Brian Marr; Prithvi Mruthyunjaya
Journal:  Surv Ophthalmol       Date:  2016-06-16       Impact factor: 6.048

5.  Conjunctival melanoma: association of cyclooxygenase-2 tumor expression to prognosis.

Authors:  Rita Pinto-Proença; Mariana Santos; Cristina Fonseca; Júlia Fernandes; Maria Filomena Gaspar; Rui Proença
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-01-02       Impact factor: 3.117

6.  [Conjunctival melanoma : Standard operating procedures in diagnosis, treatment and follow-up care].

Authors:  Jan-Peter Glossmann; Nicole Skoetz; Barbara Starbatty; Martina Bischoff; Serge Leyvraz; Henrike Westekemper; Ludwig M Heindl
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

7.  Expression of Multidrug Resistance Transporter ABCB5 in a Murine Model of Human Conjunctival Melanoma.

Authors:  Nadine E de Waard; Paraskevi E Kolovou; Sean P McGuire; Jinfeng Cao; Natasha Y Frank; Markus H Frank; Martine J Jager; Bruce R Ksander
Journal:  Ocul Oncol Pathol       Date:  2015-04

Review 8.  Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.

Authors:  Joel M Mor; Ludwig M Heindl
Journal:  Ocul Oncol Pathol       Date:  2016-12-08

9.  Melanocytic Nevus of the Tarsal Conjunctiva.

Authors:  Bülent Yazıcı; Ayşe Dolar Bilge; Ayşe Yağcı; Faisal Naqadan; Filiz Altıntepe
Journal:  Balkan Med J       Date:  2016-07-01       Impact factor: 2.021

10.  Ocular melanoma.

Authors:  Bertil E Damato; Sarah E Coupland
Journal:  Saudi J Ophthalmol       Date:  2012-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.